BMJ Publishing Group, Gut, 2(64), p. 303-311, 2014
DOI: 10.1136/gutjnl-2014-307080
Full text: Unavailable
Objective Data comparing the efficacy and safety of combination therapy with peginterferon plus low-dose ribavirin and peginterferon monotherapy in treatment-naive haemodialysis patients with hepatitis C virus genotype 2 (HCV-2) infection are limited. Design In this randomised trial, 172 patients received 24 weeks of peginterferon alfa-2a 135 mu g/week plus ribavirin 200 mg/day (n=86) or peginterferon alfa-2a 135 mu g/week (n=86). The efficacy and safety endpoints were sustained virological response (SVR) rate and adverse event (AE)-related withdrawal rate. Results Compared with monotherapy, combination therapy had a greater SVR rate (74% vs 44%, relative risk (RR): 1.68 [95% CI 1.29 to 2.20]; p= 800 000 IU/mL than those with baseline viral load